Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial
Onal et al., Turk. J. Biol., 45:518-529 (date from earlier preprint), NCT04377789(history)
Onal et al., Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial, Turk. J. Biol., 45:518-529 (date from earlier preprint), NCT04377789
RCT 447 moderate-to-severe hospitalized patients in Turkey, 52 treated with quercetin, bromelain, and vitamin C, showing no statistically significant difference in clinical outcomes. NCT04377789(history).
risk of death, 29.3% higher, RR 1.29, p = 0.57, treatment 1 of 49 (2.0%), control 6 of 380 (1.6%).
risk of ICU admission, 94.0% lower, RR 0.06, p = 0.39, treatment 0 of 49 (0.0%), control 14 of 380 (3.7%), NNT 27, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no hospital discharge, 77.8% lower, RR 0.22, p = 0.10, treatment 1 of 49 (2.0%), control 35 of 380 (9.2%), NNT 14.
Onal et al., 19 Jan 2021, Randomized Controlled Trial, Turkey, peer-reviewed, 10 authors, this trial uses multiple treatments in the treatment arm (combined with bromelain and vitamin C) - results of individual treatments may vary, trial NCT04377789(history).
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.